RNU6-231P

Across TCGA pan-cancer cohorts, RNU6-231P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RNU6-231P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-231P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-231P expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, ESCA, and SKCM are the cancer types where RNU6-231P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	IV	0.083	0.379	.001	45	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
SKCM	DFS	Tertile	III,IV	1.000	0.488	.017	18	view →
LUAD	DFS	Tertile	All	0.218	0.676	.014	18	view →
SARC	OS	Tertile	All	0.175	0.730	.009	18	view →
LIHC	DFS	Tertile	All	0.034	0.554	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNU6-231P–STAD (DFS)

Open the STAD breakdown →